ABOUT | CONTACT | LOGIN

A Prescription for Accountable Healthcare
 
P&T on DemandSM

P&T on Demand is a Clinical Pharmacy Associates program that provides both online reports and on-site implementation to assist busy directors of pharmacy, P&T chairpersons and healthcare administrators in the support of effective, efficient P&T development.

Skilled at P&T operation and formulary development, CPA gives you immediate online access to up-to-date, unbiased, committee-ready drug information reports and in-depth analyses. At the same time, on-site consulting services are available through CPA and scheduled around your P&T Committee calendar. Off-site consulting and a full complement of drug information products and services are also available from our Drug Information Center.

Adding or retaining staff to develop the materials and information required for P&T and formulary development puts a strain on the budgets of most hospital pharmacies. With P&T on Demand, you have access to the latest drug class reviews, new drug monographs, FDA safety-related labeling changes, new drug tracking system known as New Drug Classification Reports and special reports on pharmacogenomic markers, as well as drugs in the research pipeline, all helping you make critical decisions for cost-effective formulary use.

 
P&T On DemandSM Reports
Annual Subscription
The most effective way to use P&T on DemandSM is to sign up for one of our three
Annual Subscriptions. Simply click the Purchase or Subscribe button below to find out
how to receive your subscription.
Level 3  Our most comprehensive package
Ideal for P&T Committees at Hospitals, Corporate Groups of Hospitals
and Managed Care Plans

LEARN MORE »
$795
Level 2  Providing access to a wide range of reports
Ideal for Physicians Group Practices
LEARN MORE »
$395
Level 1  Providing access to necessary reports
Ideal for Individual Pharmacists, Clinical Pharmacy Depts and Physicians
LEARN MORE »
$195
Individual Reports
A wide variety P&T on DemandSM reports are available on an individual basis or in
addition to those available to you through subscription.
New Drug Classification $15 each
LEARN MORE »
CLICK HERE FOR AVAILABLE REPORTS »
Approvable/Pending Approvals Drugs and Biologics $20 each
LEARN MORE »
CLICK HERE FOR AVAILABLE REPORTS »
New Drug Evaluations $25 each
LEARN MORE »
CLICK HERE FOR AVAILABLE REPORTS »
Drug and Disease Based Class Reviews $195 each
LEARN MORE »
CLICK HERE FOR AVAILABLE REPORTS »
Highlights of Safety Related Drug Labeling Changes $30 each
LEARN MORE »
CLICK HERE FOR AVAILABLE REPORTS »
Drug Supply Shortages and Discontinuations $30 each
LEARN MORE »
CLICK HERE FOR AVAILABLE REPORTS »
 
Level 3 $795 annually
Ideal for P&T Committees at Hospitals, Corporate Groups of Hospitals and Managed Care Plans, this package gives you access to all of the following on a monthly basis:

  • 2 New Drug Evaluations
  • New Drug Classification Reports
  • Highlights of Safety Related Drug Labeling Changes
  • Drug Supply Shortages and Discontinuations
  • Approvable/Pending Approvals Drug Report
  • CPA Journal Club
  • CPA Whitepapers (expert commentary)
  • Ask the Informaticist

As a Level 3 subscriber, CPA proprietary Drug and Disease Based Class Reviews are available to you for $195 each. Additional New Drug Evaluations are available for $25 each.


Level 2 $395 annually
Ideal for Physicians Groups, this package gives you access to the following on a monthly basis:

  • New Drug Classification Report
  • Highlights of Safety Related Drug Labeling Changes
  • Drug Supply Shortages and Discontinuations
  • Approvable/Pending Approvals Drug Report
  • CPA Journal Club
  • CPA Whitepapers (expert commentary)
  • Ask the Informaticist

As a Level 2 subscriber, CPA proprietary Drug and Disease Based Class Reviews are available to you for $195 each. Additional New Drug Evaluations are available for $25 each.


Level 1 $195 annually
Ideal for Individual Pharmacists, Clinical Pharmacy Departments and Physicians, this package gives you access to the following on a monthly basis:

  • New Drug Classification Report
  • Highlights of Safety Related Drug Labeling Changes
  • Approvable/Pending Approvals Drug Report
  • CPA Journal Club
  • CPA Whitepapers (expert commentary)
  • Ask the Informaticist

As a Level 1 subscriber, CPA proprietary Drug and Disease Based Class Reviews are available to you for $195 each. Additional New Drug Evaluations are available for $25 each.


New Drug Classification
The New Drug Classification is a monthly report produced by Clinical Pharmacy Associates that lists new FDA-approved medications including indications, dosage formulations, mechanisms of action, warnings, unusual adverse events, dosage and administration, average wholesale price (AWP) and a list of therapeutic alternatives.

Each report is created by our team of experienced clinical pharmacists using FDA Center for Drug Evaluation and Research (CDER) and other supplemental expert resources. Our professionals review these websites throughout the month to issue monthly reports.

The most up-to-date new drug compilation available, the NDC Report provides information that's critical for pharmacists, P&T Committees, physicians and drug benefit managers. Among its many benefits, it:

  • Informs healthcare professionals on the latest in newly approved drugs, indications and formulations
  • Assists busy P&T Committees in defining time-lines for formulary review on a monthly basis
  • Comes complete with a drug ranking system for timely formulary decisions


Approvable Pending Drugs and Biologics
This report enables health care organizations to meet the financial and clinical pressures associated with the entrance onto the market of new drugs and biologics. Given the fact that these new therapies can represent significant cost, they warrant intense scrutiny and planning. A recent example is the autologous cellular immunotherapy Provenge® (Sipuleucel-T) approved by the FDA in April 2010 for men with advanced prostate cancer. Studies indicate it can prolong life by approximately four months, but at a cost of $93,000 per patient.

The advantage of the Approvable or Pending Approvable Drugs and Biologics report include:

  • Support proactive methods for handling specific products prior to FDA approval and market release
  • Consideration of the effects of these agents on current formulary products
  • Ability to schedule future drug and class reviews for acceptance to formulary
  • Anticipate budgetary concerns for expensive agents


New Drug Evaluations (Drug Monographs)
Clinical Pharmacy Associates' Drug Monographs provide the most up-to date clinical information on new drugs approved by the FDA. A useful source of drug information for patient care, they enable clinical decision makers to make better formulary decisions.

To produce the Monographs, our expert clinicians research original clinical articles along with FDA-approved information from pharmaceutical manufacturers. We also provide periodic updates to these reviews. In combination with our New Drug Classification reports, they provide timely drug information accessibility to formulary decision makers and clinicians in hospital, managed care and ambulatory settings.

Drug and Disease-Based Drug Class Reviews
Clinical Pharmacy Associates provides information about drug treatment regardless of therapeutic class for various diseases and conditions. The information is important for:

  • Promoting evidence-based medicine
  • Formulary decision making
  • Treatment protocol development


To generate the information, CPA drug review experts evaluate the clinical literature from a diseases-and-conditions perspective and develop unique comparisons across therapeutic drug classes. Comparative analyses of clinical trials, adverse drug events and clinical efficacy of various therapies are included in the process. Examples include Treatment of Inflammatory Bowel Syndrome, Medications for Bioterrorism and Medications for the Treatment of Depression.

Comparing drug therapies from a disease-based perspective more closely simulates how practitioners treat patients. Our unique approach has proven effective for hospitals, managed care organizations, P&T committees, pharmacy departments, ambulatory care organizations, pharmacies and practitioners.

Highlights of Safety-Related Drug Labeling Changes
Safety-Related Drug Labeling Changes is a monthly report from Clinical Pharmacy Associates that provides a list of drug products with safety labeling changes to any of the following: Boxed Warning, Contraindications, Warnings, Precautions, Adverse Reaction, Patient Package insert/Medication Guide. The report provides critical information to pharmacists, P&T Committees, physicians, nurses and drug benefit managers:
 

  • Informs healthcare professionals about the latest updates to a drug's package insert
  • Helps P&T Committees make changes to their formulary based on the latest available clinical data
  • Serves as a preventive alert mechanism for healthcare professionals providing better awareness regarding patient safety and adverse drug reactions
  • Helps healthcare institutions meet Joint Commission standard MM


A team of experienced CPA pharmacists regularly monitors MedWatch Safety Information/Safety Related Drug Labeling Changes and other supplemental expert resources to create the reports. Throughout the month, team members review these websites in order to be able to provide timely updated reports.

Drug Supply Shortages and Discontinuations
Drug supply shortages continue to present a challenge to all healthcare professionals. Interruptions in volume and the type of medications available to patients have increased in recent years. Therefore, greater attention to the subject is now warranted to ensure optimal pharmaceutical care for patients and to maintain patient safety. Supply shortages vary nationwide between regions and between governmental and non-governmental organizations. Click here to see an example of just a few of the drugs in short-supply for 2010. The CPA Analytics subscription can bring you the comprehensive list of Drug Supply Shortages and Discontinuations, an essential tool in your hospital development.

 
 
© 2011 Clinical Pharmacy Associates, Inc.  |  About  |  Services & Products  |  Clients  |  Contact  |  End User Agreement  |  Legal